- [5] Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 1998;279:1181–6.
- [6] International Primary Care Airways Group (IPAG). Chronic Airways Disease: A Guide for Primary Care Physicians. IPAG Diagnosis & Management Handbook. 2005.
- [7] Price D, Bond C, Bouchard J, Costa R, Keenan J, Levy ML, et al. International Primary Care Respiratory Group (IPCRG) Guidelines: Management of Allergic Rhinitis. Prim Care Resp J 2006;15(1):58–70.

Dr Peter G. Polos*
 Senior Medical Director, Merck & Co., Inc.,
 Whitehouse Station, New Jersey, NJ 08889, USA

*Tel.: +1 908 423 3473; fax: +1 908 823 3423.
 E-mail address: Peter.Polos@merck.com

4 May 2006

doi:10.1016/j.pcrj.2006.07.003

The role of Montelukast as monotherapy in paediatric asthma – IPCRG Guideline authors' response

Dear Sir,

We would like to thank Dr Polos for his critical reading of the IPCRG guidelines. The process of making guidelines for a worldwide primary care audience should be reliable, fair, and independent. Moreover, suggestions for treatment should be evidence-based, acceptable to physicians who need to have a degree of ownership of them, and guidelines need to be within reach of the public whom they serve as primary care physicians. Dr Polos states that there is evidence for the treatment of paediatric asthma with the leukotriene antagonist (LTRA) Montelukast. Indeed the study from Knorr et al. in children between 2 and 5 years old shows a favourable effect for montelukast as compared to placebo [1], and the Bisgaard et al. study in the same age group shows a reduction in the number of exacerbations [2].

However, based on these two studies alone, the IPCRG Guideline Committee did not feel that there was substantial and sufficient evidence to recommend Montelukast as monotherapy in children between the age of 2 and 5 years. We had several reasons for this decision. These studies [1,2] were not performed in primary care, which meant that we could not extrapolate these results to the very variable group of patients in primary care. Secondly, we still need a direct comparison between the effect of inhaled corticosteroids (ICS) in this age group and the effect of LTRAs. In the older age group of 6–14 years, the MOSAIC study showed a non-inferiority between Montelukast monotherapy and low dose ICS. However, this study has been heavily criticised [3]. An independent direct comparison

between montelukast and low dose ICS [4] also in the older age group showed clearly that low dose ICS treatment has superior effects on inflammation, clinical, and pulmonary outcomes as compared to Montelukast. Although the benefit of prescribing a tablet once-daily – as opposed to the complicated requirements of learning how to inhale both short-acting beta-agonists and corticosteroids – is very clear to us as primary care physicians, we still believe that monotherapy with LTRAs has not been proven enough for it to be recommended in global primary care guidelines. What we need is evidence on a primary care level with primary care patients, and we would encourage MSD to perform a direct comparison between Montelukast and ICS in the preschool age group.

References

- [1] Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of asthma in children aged 2 to 5 years. Pediatrics 2001;108(3):E48.
- [2] Bisgaard H, Zielen S, Garcia-Garcia M, et al. Montelukast reduces asthma exacerbations in 2- to 5- year-old children with intermittent asthma. Am J Respir Crit Care Med 2005;171:315–22.
- [3] Goodman DC. When an asthma drug has an inferiority complex: a noninferiority trial. Pediatrics 2005;116(2):493–5.
- [4] Zeiger RS, Bird SR, Kaplan MS, et al. Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial. Am J Med 2005;118(6):649–57.

Thys van der Molen*
 Department of General Practice, University
 Medical Center, Groningen, Antonius Deusinglaan 1,
 9713 AV, Groningen, The Netherlands

C.P. Onno van Schayck
 Care and Public Health Research institute (Caphri),
 University of Maastricht, The Netherlands

Anders Østrem
*Department of General Practice,
University of Aberdeen, United Kingdom*

Marianne Østergaard
*Department of General Practice,
University of Copenhagen, Denmark*

* Corresponding author. Tel.: +31 503 637 478;
fax: +31 503 632 964.

E-mail address: t.van.der.molen@med.umcg.nl
(T. van der Molen)

10 July 2006

doi:10.1016/j.pcrj.2006.07.006

Available online at www.sciencedirect.com

Available online at <http://www.thepcrj.com>

Copyright General Practice Airways Group
Reproduction prohibited